Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience
Therapeutic Advances in Gastroenterology · 2024-01 · 17
DOI: 10.1177/17562848241284051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Gastroenterology, online erschienen am 28.09.2024. Verfasst von Kim Wagner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background
There is an increasing diversification in the treatment landscape for inflammatory bowel diseases (IBD) leading to therapeutic challenges that can only incompletely be covered by prospective randomized double-blind trials. Real-world observations are therefore an important tool to provide insights into therapeutic strategies.
Objectives
To describe the real-world treatment algorithms in an IBD referral centre.
Design
Single-centre retrospective cohort study.
Methods
We retrospectively analysed prospectively collected data on treatment sequences and outcomes from 502 patients with Crohn’s disease (CD) and ulcerative colitis (UC) treated with infliximab, adalimumab, vedolizumab or ustekinumab at a large German tertiary referral centre.
Results
Treatment decisions correlated to baseline patient characteristics. Over time, infliximab continued to be the preferred first-line option in CD and UC, although ustekinumab and vedolizumab, respectively, became increasingly important choices. Remission rates decreased with the advancement of therapy lines.
Conclusion
We provide insights into the evolution of tertiary centre real-world treatment sequences that might – together with other observations – help to guide the selection of therapies in IBD. Our data also strongly underscore the unmet need for biomarkers supporting treatment decisions.
Trial registration
None.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
- Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.
- Department of Medicine 1, Friedrich-Alexander University Erlangen-Nuremberg, Ulmenweg 18, Erlangen, D-91054, Germany.
ORCID-Profile: Tanja M Müller, Sarah Fischer, Raja Atreya, Sebastian Zundler
Förderung
- Else Kröner-Fresenius-Stiftung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Wagner, K., Müller, T. M., Vitali, F., Fischer, S., Haberkamp, S., Rouse-Merkel, R., Atreya, R., Neurath, M. F., & Zundler, S. (2024). Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience. Therapeutic Advances in Gastroenterology, 17. https://doi.org/10.1177/17562848241284051
Vancouver
Wagner K, Müller TM, Vitali F, Fischer S, Haberkamp S, Rouse-Merkel R, et al. Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience. Therapeutic Advances in Gastroenterology. 2024;17. doi:10.1177/17562848241284051
BibTeX
@article{Wagner2024,
author = {Wagner, Kim and Müller, Tanja M and Vitali, Francesco and Fischer, Sarah and Haberkamp, Sophie and Rouse-Merkel, Rachel and Atreya, Raja and Neurath, Markus F and Zundler, Sebastian},
title = {Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience},
journal = {Therapeutic Advances in Gastroenterology},
year = {2024},
volume = {17},
doi = {10.1177/17562848241284051}
}
EUVIMED